About
Technology
Issues
FAQ
Links
Official Page
Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with
ERBB2
amplification or overexpression: Results from the TAPUR Study.
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.